Actively personalized vaccination trial for newly diagnosed glioblastoma.

Adult Aged Antigens, Neoplasm / immunology CD8-Positive T-Lymphocytes / immunology Cancer Vaccines / immunology Epitopes, T-Lymphocyte / immunology Female Glioblastoma / diagnosis HLA-A Antigens / immunology Humans Immunologic Memory / immunology Male Middle Aged Precision Medicine / methods T-Lymphocytes, Helper-Inducer / immunology Treatment Outcome

Journal

Nature

ISSN: 1476-4687

Titre abrégé: Nature

Pays: England

ID NLM: 0410462

Informations de publication

Date de publication:
01 2019

Historique:

received: 08 05 2018

accepted: 19 11 2018

pubmed: 21 12 2018

medline: 8 5 2019

entrez: 21 12 2018

Statut: ppublish

Résumé

Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors

Identifiants

DOI: 10.1038/s41586-018-0810-y PMID: 30568303

pubmed: 30568303

doi: 10.1038/s41586-018-0810-y

pii: 10.1038/s41586-018-0810-y

doi:

Substances chimiques

Antigens, Neoplasm 0

Cancer Vaccines 0

Epitopes, T-Lymphocyte 0

HLA-A Antigens 0

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

240-245

Subventions

Organisme : Medical Research Council

ID : MR/P024351/1

Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Type : ErratumIn

Références

Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).

doi: 10.1056/NEJMoa1003466

Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).

doi: 10.1056/NEJMoa1412082

Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).

doi: 10.1056/NEJMoa1406498

Quail, D. F. & Joyce, J. A. The microenvironmental landscape of brain tumors. Cancer Cell 31, 326–341 (2017).

doi: 10.1016/j.ccell.2017.02.009

Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).

doi: 10.1038/nature12477

Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).

doi: 10.1038/nature23003

Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).

doi: 10.1038/nature22991

Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).

doi: 10.1126/science.aaa4971

Yadav, M. et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515, 572–576 (2014).

doi: 10.1038/nature14001

Freudenmann, L. K., Marcu, A. & Stevanović, S. Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry. Immunology 154, 331–345 (2018).

doi: 10.1111/imm.12936

Bouffet, E. et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol. 34, 2206–2211 (2016).

doi: 10.1200/JCO.2016.66.6552

Johanns, T. M. et al. Immunogenomics of hypermutated glioblastoma: a patient with germline POLE deficiency treated with checkpoint blockade immunotherapy. Cancer Discov. 6, 1230–1236 (2016).

doi: 10.1158/2159-8290.CD-16-0575

Platten, M., Bunse, L., Wick, W. & Bunse, T. Concepts in glioma immunotherapy. Cancer Immunol. Immunother. 65, 1269–1275 (2016).

doi: 10.1007/s00262-016-1874-x

Okada, H. et al. Induction of CD8

doi: 10.1200/JCO.2010.30.7744

Weller, M. et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat. Rev. Neurol. 13, 363–374 (2017).

doi: 10.1038/nrneurol.2017.64

Rampling, R. et al. A Cancer Research UK first time in human phase I trial of IMA950 (novel multi peptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin. Cancer Res. 22, 4776–4785 (2016).

doi: 10.1158/1078-0432.CCR-16-0506

Weinschenk, T. et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62, 5818–5827 (2002).

pubmed: 12384544

Dutoit, V. et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain 135, 1042–1054 (2012).

doi: 10.1093/brain/aws042

Morse, M. A. et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17, 4844–4853 (2011).

doi: 10.1158/1078-0432.CCR-11-0891

Lawson, D. H. et al. Randomized, placebo-controlled, phase III trial of yeast-derived granulocyte–macrophage colony-stimulating factor (GM-CSF) versus peptide vaccination versus GM-CSF plus peptide vaccination versus placebo in patients with no evidence of disease after complete surgical resection of locally advanced and/or stage IV melanoma: a trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J. Clin. Oncol. 33, 4066–4067 (2015).

doi: 10.1200/JCO.2015.62.0500

Woroniecka, K. et al. T-cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clin. Cancer Res. 24, 4175–4186 (2018).

doi: 10.1158/1078-0432.CCR-17-1846

Hadrup, S. R. et al. Tumor infiltrating lymphocytes in seminoma lesions comprise clonally expanded cytotoxic T cells. Int. J. Cancer 119, 831–838 (2006).

doi: 10.1002/ijc.21894

Thor Straten, P. et al. Identification of identical TCRs in primary melanoma lesions and tumor free corresponding sentinel lymph nodes. Cancer Immunol. Immunother. 55, 495–502 (2006).

doi: 10.1007/s00262-005-0023-8

Kalaora, S. et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7, 5110–5117 (2016).

doi: 10.18632/oncotarget.6960

Tran, E. et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350, 1387–1390 (2015).

doi: 10.1126/science.aad1253

Weller, M. et al. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 18, 1373–1385 (2017).

doi: 10.1016/S1470-2045(17)30517-X

Shraibman, B. et al. Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol. Cell. Proteomics 17, 2132–2145 (2018).

doi: 10.1074/mcp.RA118.000792

Singh-Jasuja, H., Emmerich, N. P. & Rammensee, H. G. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. Cancer Immunol. Immunother. 53, 187–195 (2004).

doi: 10.1007/s00262-003-0480-x

Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).

doi: 10.1056/NEJMoa043330

Walter, S. et al. Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres. J. Immunol. 171, 4974–4978 (2003).

doi: 10.4049/jimmunol.171.10.4974

Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics 25, 1754–1760 (2009).

doi: 10.1093/bioinformatics/btp324

Langmead, B., Trapnell, C., Pop, M. & Salzberg, S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).

doi: 10.1186/gb-2009-10-3-r25

Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L. & Wold, B. Mapping and quantifying mammalian transcriptomes by RNA-seq. Nat. Methods 5, 621–628 (2008).

doi: 10.1038/nmeth.1226

Kim, Y. et al. Immune epitope database analysis resource. Nucleic Acids Res. 40, W525–W530 (2012).

doi: 10.1093/nar/gks438

Kreiter, S. et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature 520, 692–696 (2015).

doi: 10.1038/nature14426

Koressaar, T. & Remm, M. Enhancements and modifications of primer design program Primer3. Bioinformatics 23, 1289–1291 (2007).

doi: 10.1093/bioinformatics/btm091

Untergasser, A. et al. Primer3—new capabilities and interfaces. Nucleic Acids Res. 40, e115 (2012).

doi: 10.1093/nar/gks596

Kent, W. J. BLAT—the BLAST-like alignment tool. Genome Res. 12, 656–664 (2002).

doi: 10.1101/gr.229202

Stupp, R., Brada, M., van den Bent, M. J., Tonn, J. C. & Pentheroudakis, G. High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25, iii93–iii101 (2014).

doi: 10.1093/annonc/mdu050

Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972 (2010).

doi: 10.1200/JCO.2009.26.3541

Rodenko, B. et al. Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat. Protoc. 1, 1120–1132 (2006).

doi: 10.1038/nprot.2006.121

Hadrup, S. R. et al. Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat. Methods 6, 520–526 (2009).

doi: 10.1038/nmeth.1345

Walter, S. et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. 18, 1254–1261 (2012).

doi: 10.1038/nm.2883

Bertoletti, A. et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J. Virol. 67, 2376–2380 (1993).

pubmed: 7680391 pmcid: 240403

Livingston, B. D. et al. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J. Immunol. 159, 1383–1392 (1997).

pubmed: 9233635

Welters, M. J. et al. Harmonization of the intracellular cytokine staining assay. Cancer Immunol. Immunother. 61, 967–978 (2012).

doi: 10.1007/s00262-012-1282-9

Zhu, J., Yamane, H. & Paul, W. E. Differentiation of effector CD4 T cell populations. Annu. Rev. Immunol. 28, 445–489 (2010).

doi: 10.1146/annurev-immunol-030409-101212

Loffler, M. W. et al. Personalized peptide vaccine induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J. Hepatol. 65, 849–855 (2016).

doi: 10.1016/j.jhep.2016.06.027

Widenmeyer, M. et al. Promiscuous survivin peptide induces robust CD4

doi: 10.1002/ijc.26365

Grimm, E. A. et al. Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype. Cancer Immunol. Immunother. 32, 391–399 (1991).

doi: 10.1007/BF01741334

Britten, C. M. et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8

doi: 10.1007/s00262-007-0378-0

van der Burg, S. H. et al. Harmonization of immune biomarker assays for clinical studies. Sci. Transl. Med. 3, 108ps44 (2011).

pubmed: 22072636

Thor Straten, P. et al. In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J. Immunol. 163, 443–447 (1999).

pubmed: 10384147

Kobayashi, E. et al. A new cloning and expression system yields and validates TCRs from blood lymphocytes of patients with cancer within 10 days. Nat. Med. 19, 1542–1546 (2013).

doi: 10.1038/nm.3358

Cohen, C. J. et al. Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond. Cancer Res. 67, 3898–3903 (2007).

doi: 10.1158/0008-5472.CAN-06-3986

Stanke, J. et al. A flow cytometry-based assay to assess minute frequencies of CD8

doi: 10.1016/j.jim.2010.06.005

Santegoets, S. J. et al. Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry. Cancer Immunol. Immunother. 64, 1271–1286 (2015).

doi: 10.1007/s00262-015-1729-x